(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model

CTLA-4 & survival in a colorectal cancer model

April 14, 2023

Abstract

Systemic therapy with CTLA-4 blocking antibody (aCTLA4) restores endogenous anti tumor immunity and induces remarkable long-term clinical benefits in patients with melanoma. Yet immune-related side effects remain a major hurdle to extend its label to many more types of cancer. Intra- and peritumoral administration of aCTLA4 has recently emerged to optimize its dose/efficacy ratio while preventing its on-target, off-tumor systemic toxicities. Sustained delivery of low dose aCTLA4 by genetically engineered encapsulated cells (MVX-3) could offer a promising option for cancer treatment addressing the shortcomings of systemic therapy.

Related products

Catalogue product

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Customized product

No items found.
Related posters